Jerusalem Pharmaceuticals Valuation
Is JPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JPH?
Other financial metrics that can be useful for relative valuation.
|What is JPH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does JPH's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
PHARMACARE Dar Al-Shifa Pharmaceuticals
BPC Birzeit Pharmaceuticals
BJP Beit Jala Pharmaceutical
A014570 Korean Drug
JPH Jerusalem Pharmaceuticals
Price-To-Earnings vs Peers: JPH is good value based on its Price-To-Earnings Ratio (8.1x) compared to the peer average (9.2x).
Price to Earnings Ratio vs Industry
How does JPH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price to Earnings Ratio vs Fair Ratio
What is JPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||8.1x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JPH's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of JPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JPH ($3.5) is trading below our estimate of fair value ($15.47)
Significantly Below Fair Value: JPH is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.